Masimo delivered Q3 results that mostly aligned with guidance, yet it faces challenges in its non-healthcare segment.

Shares of Masimo Co. (NASDAQ:MASI – Get Free Report) have received an average rating of “Moderate Buy” from the seven ...

Separately, a Delaware jury in late October found that Masimo’s current products did not infringe any of Apple’s patents. The ...

Executives said the patient monitoring company’s consumer business will likely become a discontinued operation if it is not ...

Masimo (Nasdaq:MASI) shares ticked up before hours today on third-quarter results that came in ahead of the consensus ...

Masimo Corp. ( (MASI) ) has released its Q3 earnings. Here is a breakdown of the information Masimo Corp. presented to its investors. Masimo ...

Revenue: US$504.6m (up 5.4% from 3Q 2023). Net income: US$9.80m (down 7.5% from 3Q 2023). Profit margin: 1.9% (down from 2.2% in 3Q 2023). The decrease in margin was driven by higher expenses. EPS ...

Young said Masimo is lowering corporate overhead costs, with cuts such as selling the corporate jet and reducing marketing expenses for products that aren't producing meaningful revenue and returns.

Apple and Masimo's patent and trade secret dispute has intensified through lawsuits as Apple defends its innovations and Masimo's claims are rejected in court. Apple and medical equipment maker ...

We recently published a list of 8 Most Promising Medical Stocks According to Hedge Funds. In this article, we are going to take a look at where Masimo Corporation (NASDAQ:MASI) stands against ...

In a report released today, Marie Thibault from BTIG maintained a Buy rating on Masimo (MASI – Research Report), with a price target of ...

Ladies and gentlemen, good afternoon, and welcome to Masimo's Third Quarter 2024 Earnings ... Next, our review of the product portfolio and R&D projects is ongoing. But the headline is that ...